BioSpace News Archive

Antisense Therapeutics (ASX: ANP/OTC: ATHJY) is pleased to advise that additional preliminary data analyses from the seven patients who have completed their 24 weeks of dosing in the ATL1102 Phase II DMD clinical trial was presented by Dr Ian Woodcock, the Principle Investigator of the ATL1102 Phase II trial at the 2019 Action Duchenne International Conference, Hinkley, UK on 15 November 2019.

In an effort to drive collaboration between Providers and community partners, Inland Empire Health Plan (IEHP) recently hosted a dynamic and thought-provoking conference on the state of health care in the region.

XRHealth, the leading provider of extended reality and therapeutic AR and VR applications for the medical industry, announced today that American International College conducted research that found that XRHealth’s VR Therapy proved to be a more reliable clinical tool for physical therapy examination than the goniometric method, the current industry standard.

To help identify and scale new evidence-based techniques to improve clinical outcomes around wound care, Advocate Aurora Health’s Post-Acute Division is advancing customized education through a collaboration with Medline for more than 400 nurses across Illinois and Wisconsin.

A better solution must be found: 95% of the doctors participating in the Frost & Sullivan marketing survey, admitted that currently available pessaries and surgery are not satisfactory treatments for POP, mainly because of side effects from pessary usage and associated complications of surgery

The center will offer one of the most promising new cancer therapies available, proton therapy; and will utilize the latest advancement in proton therapy systems, the ProNova SC360 manufactured by ProNova Solutions, LLC located in Maryville, Tennessee

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Lipocine Inc. and certain of its officers, on behalf of shareholders who purchased Lipocine securities purchased between March 27, 2019, and November 8, 2019, both dates inclusive.

Group of seven new attorneys arrive with substantial patent and regulatory expertise to address legal issues related to dietary supplements and CBD

BioCryst Pharmaceuticals, Inc. announced the completion of an underwritten public offering of 43,620,690 shares of its common stock, including 5,689,655 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.

A stunning revelation came back in April, when an Oxford published study pointed to only 3% of the cancer drugs tested between 2000 and 2015 were approved to treat patients, whereas another study released this September posited the reason for this level of failure laying with scientists incorrectly targeting.